A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments 100 base pairs or greater in length; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments.

The present invention provides a live, attenuated coronavirus comprising a mutation in non-structural protein nsp-3 and/or deletion of accessory proteins 3a and 3b. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.

The present disclosure provides a method for rapid preparation of an epidemic infectious bronchitis vaccine. An infectious clone of an infectious bronchitis virus (IBV) H120 vaccine strain is used as a skeleton carrier and an antigen gene in the skeleton carrier is replaced with a target antigen gene of an epidemic infectious bronchitis virus strain, to obtain a recombinant bronchitis virus. The target antigen gene is an S1 gene or an S gene. The S gene is one of the S gene fragments of the epidemic infectious bronchitis virus strain or a fusion gene composed of multiple S gene fragments. Furthermore, the target antigen gene and an N gene can be simultaneously replaced and a signal peptide region of the original S1 gene in the skeleton carrier is retained during the replacement.

A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments related to Civet SARS, Bat Sars, and BtRs and BtRI BetaCov; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Microneedle and microneedle devices including implantable tips (e.g., silk-based tips) for sustained dermal delivery of a coronavirus and/or influenza vaccine, kits, as well as methods of manufacturing and using the same are described herein. In other embodiments, compositions and methods for controlled- or sustained-administration of a coronavirus vaccine and/or an influenza vaccine to provide improved immunogenicity and/or broad-spectrum immunity to a subject are also described.

A vaccine candidate is herein described comprised by statistically significant DNA fragments related to Civet SARS, Bat Sars, and BtRs BetaCov, BtRI BetaCov, and Neoromicia resulting in three types of compositions: 1) a composition of statistically significant DNA fragments, 2) a composition of RNA transcripts corresponding to the statistically significant DNA fragments, and 3) a computational reduction composition wherein the DNA fragments are fully or partially subtracted from a base organism, resulting in a synthetic organism which has a high statistical likelihood of problematic functions being partially or fully removed.

This invention relates to SARS-CoV-2 viruses adapted with nanoluciferase reporter molecules and mouse-adapted SARS-CoV-2 viruses, compositions including the same and methods of use thereof.

The invention relates generally to chimeric viral fusion proteins comprising the ectodomain and optionally the transmembrane domain of a first viral fusion protein (e.g., a spike protein of a coronavirus) and the cytoplasmic domain of a second viral fusion protein (e.g. RSV), immunogenic compositions comprising such chimeric proteins, and methods of use of same.

The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.